EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Singleton mutations in large-scale cancer genome studies: uncovering the tail of cancer genome

Sanket Desai iD, Suhail Ahmad, Bhargavi Bawaskar, Sonal Rashmi, Rohit Mishra, Deepika Lakhwani, Amit Dutt iD

NAR Cancer · 2024

DOI: 10.1093/narcan/zcae010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2024. Verfasst von Sanket Desai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai 410210, Maharashtra, I…. Hauptthemen laut MEDLINE: Neoplasms, Mutation, Genome, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Department of Atomic Energy, Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Singleton or low-frequency driver mutations are challenging to identify. We present a domain driver mutation estimator (DOME) to identify rare candidate driver mutations. DOME analyzes positions analogous to known statistical hotspots and resistant mutations in combination with their functional and biochemical residue context as determined by protein structures and somatic mutation propensity within conserved PFAM domains, integrating the CADD scoring scheme. Benchmarked against seven other tools, DOME exhibited superior or comparable accuracy compared to all evaluated tools in the prediction of functional cancer drivers, with the exception of one tool. DOME identified a unique set of 32 917 high-confidence predicted driver mutations from the analysis of whole proteome missense variants within domain boundaries across 1331 genes, including 1192 noncancer gene census genes, emphasizing its unique place in cancer genome analysis. Additionally, analysis of 8799 TCGA (The Cancer Genome Atlas) and in-house tumor samples revealed 847 potential driver mutations, with mutations in tyrosine kinase members forming the dominant burden, underscoring its higher significance in cancer. Overall, DOME complements current approaches for identifying novel, low-frequency drivers and resistant mutations in personalized therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMutationGenome, HumanHumansGenomics

Autor:innen und Institutionen

  • Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai 410210, Maharashtra, India.
  • Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, Maharashtra, India.
  • Department of Genetics, University of Delhi, South Campus, New Delhi 110021, India.

ORCID-Profile: Sanket Desai, Amit Dutt

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Department of Atomic Energy, Government of India

Zitieren

APA

Desai, S., Ahmad, S., Bawaskar, B., Rashmi, S., Mishra, R., Lakhwani, D., & Dutt, A. (2024). Singleton mutations in large-scale cancer genome studies: uncovering the tail of cancer genome. NAR Cancer. https://doi.org/10.1093/narcan/zcae010

Vancouver

Desai S, Ahmad S, Bawaskar B, Rashmi S, Mishra R, Lakhwani D, et al. Singleton mutations in large-scale cancer genome studies: uncovering the tail of cancer genome. NAR Cancer. 2024. doi:10.1093/narcan/zcae010

BibTeX
@article{Desai2024,
  author = {Desai, Sanket and Ahmad, Suhail and Bawaskar, Bhargavi and Rashmi, Sonal and Mishra, Rohit and Lakhwani, Deepika and Dutt, Amit},
  title = {Singleton mutations in large-scale cancer genome studies: uncovering the tail of cancer genome},
  journal = {NAR Cancer},
  year = {2024},
  doi = {10.1093/narcan/zcae010}
}
Kostenlos starten →